GBC Business Summary

Golden Biotechnology Corp. (GBC) is a Taiwan-based clinical-stage biopharmaceutical company that generates revenue through a dual-track business model comprising innovative drug development and the commercialization of evidence-based health supplements. The company’s primary business segments are its pharmaceutical R&D pipeline, centered on its proprietary small molecule new chemical entity (NCE) Antroquinonol (HOCENA), and its consumer health division, which markets specialized supplements such as Liverty for liver health and Rasle for immune support. GBC’s pharmaceutical efforts target high-unmet-need areas including oncology (pancreatic cancer, AML, and NSCLC), infectious diseases, and neurodegenerative disorders, utilizing a flexible biotech model focused on out-licensing and strategic partnerships. Within the Taiwanese biotech landscape, GBC competes with major players such as PharmaEssentia, Caliway Biopharmaceuticals, and Bora Pharmaceuticals, positioning itself as a niche specialist in fungal-derived small molecule therapeutics. The company was founded in 2002 by Sheng Yung Liu (Alex Liu) and Li Yu Wu, who established GBC’s core screening platforms for discovering bioactive compounds from Antrodia camphorata. As of March 2026, the leadership team is led by Founder and Chairman Sheng Yung Liu and General Manager BK Choy, who serves as the primary executive overseeing global market expansion and strategic execution. Other key leaders include Chief Scientific Officer YL Tai, Ph.D., who directs advanced research initiatives, and Vice President of Research Wu-Che Wen, Ph.D., a central figure in the development of the Antroquinonol pipeline. Financial strategy and corporate communications are managed by CFO and Spokesperson Eric Lin. GBC is a publicly traded entity on the Taipei Exchange (TPEx) and maintains a global presence with offices in the United States and manufacturing facilities that adhere to PIC/S GMP standards.